尔康制药
(300267)
| 流通市值：41.96亿 | | | 总市值：60.85亿 |
| 流通股本：14.22亿 | | | 总股本：20.63亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 946,176,929.97 | 567,555,422.78 | 247,387,142.02 | 1,165,761,300.56 |
| 营业总成本 | 871,286,149.56 | 531,027,229.43 | 241,298,499.46 | 1,164,383,715.31 |
| 其他经营收益 | | | | |
| 营业利润 | 69,484,854.78 | 39,881,363.73 | 10,259,474.29 | -365,034,739.02 |
| 利润总额 | 68,705,105.59 | 40,533,569.6 | 10,238,525.54 | -367,816,058.78 |
| 净利润 | 57,020,515.95 | 33,887,289.91 | 9,431,220.1 | -399,311,259.91 |
| 每股收益 | | | | |
| 其他综合收益 | -21,620,512.8 | -55,824,276.59 | -25,060,678.8 | -33,376,075.86 |
| 综合收益总额 | 35,400,003.15 | -21,936,986.68 | -15,629,458.7 | -432,687,335.77 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 1,962,470,795.66 | 1,973,524,498.1 | 1,919,148,658.08 | 1,788,564,901.24 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,079,654,155.86 | 3,006,303,485.97 | 3,040,340,952.72 | 3,072,459,344.96 |
| 资产总计 | 5,042,124,951.52 | 4,979,827,984.07 | 4,959,489,610.8 | 4,861,024,246.2 |
| 流动负债: | | | | |
| 流动负债合计 | 953,591,209.27 | 949,999,889.2 | 916,906,089.4 | 802,726,936.71 |
| 非流动负债: | | | | |
| 非流动负债合计 | 77,997,607.34 | 76,685,830.62 | 83,267,263.87 | 84,242,211.94 |
| 负债合计 | 1,031,588,816.61 | 1,026,685,719.82 | 1,000,173,353.27 | 886,969,148.65 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,084,395,985.6 | 4,022,424,377.82 | 4,022,178,265.1 | 4,034,293,235.18 |
| 股东权益合计 | 4,010,536,134.91 | 3,953,142,264.25 | 3,959,316,257.53 | 3,974,055,097.55 |
| 负债和股东权益合计 | 5,042,124,951.52 | 4,979,827,984.07 | 4,959,489,610.8 | 4,861,024,246.2 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,067,558,834.51 | 535,952,224.49 | 263,400,613.21 | 1,492,447,126.22 |
| 经营活动现金流出小计 | 1,041,885,770.53 | 690,001,743.25 | 273,318,755.06 | 1,234,762,154.91 |
| 经营活动产生的现金流量净额 | 25,673,063.98 | -154,049,518.76 | -9,918,141.85 | 257,684,971.31 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 335,278,183.13 | 312,050,387.91 | 170,338,917.27 | 1,115,513,273.71 |
| 投资活动现金流出小计 | 420,935,925.89 | 318,826,880.25 | 204,797,831.2 | 1,243,980,195.38 |
| 投资活动产生的现金流量净额 | -85,657,742.76 | -6,776,492.34 | -34,458,913.93 | -128,466,921.67 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,097,091,609.98 | 672,950,000 | 355,750,000 | 949,937,821 |
| 筹资活动现金流出小计 | 1,041,052,895.4 | 663,033,201.28 | 313,068,556.69 | 981,477,007.85 |
| 筹资活动产生的现金流量净额 | 56,038,714.58 | 9,916,798.72 | 42,681,443.31 | -31,539,186.85 |
| 汇率变动对现金及现金等价物的影响 | -2,552,831.9 | -382,825.31 | -545,998.75 | -3,364,598.62 |
| 现金及现金等价物净增加额 | -6,498,796.1 | -151,292,037.69 | -2,241,611.22 | 94,314,264.17 |
| 期末现金及现金等价物余额 | 577,724,492.85 | 432,931,251.26 | 581,981,677.73 | 584,223,288.95 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -151,292,037.69 | - | 94,314,264.17 |